NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

I think the issue simply is that the interim DCVax-L blinded blended trial measured from surgery, hence, its KM curve was from surgery.

So when I overlaid the curve from that study on LL's latest chart with its various control arms, ex et al wanted the DCVax-L curve shifted to the left by 3 months to accommodate for the 3 month screening process that took place after surgery - when comparing that curve to the others. And when I shifted the DCVax-L interim blended treatment and control curve to the left by 3 months, it still beats the other curves.

I would be certain that when the final comparisons come out, the highly qualified stat people will have ensured that all curves will have an equal starting point.